Back to top

Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next

Biomea Fusion Inc ($BMEA) announced an update on their ongoing clinical study. Biomea Fusion Inc. has completed a mid-stage study of BMF-219 in adu...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Biomea Fusion, Inc. (BMEA)